Abstract
This is the first study performed in Murcia (south-eastern Spain) in which 592 families with hereditary breast and ovarian cancer were identified thanks to Genetic Counselling Units from this area over 6 years. Diagnostic performance was 18.1% and 194 different genetic variants were obtained. Variants with uncertain significance accounted for only 5.6% of the total number of reports, so our population has been well characterised. In BRCA1 gene, two novel variants were found (c.1859delT and c.3205C > T) and the most frequently detected mutations were c.68_69delAG, c.212 + 1G > A, c.5123C > A, c.211A > G and c.1918C > T, which together represented 56.67% of total pathogenic mutations. In BRCA2 gene, four recurrent variants were described (deletion of entire exon 2, c.9117G > A, c.3264dupT and c.3455T > G) representing 43.5% of the mutations in this gene. Mutation c.68_69delAG and deletion of entire exon 2 in BRCA1 and BRCA2 genes respectively were the most prevalent variants in our population. Regarding the genotype-phenotype relation, mutation c.212 + 1G > A appeared in an important percentage of breast and ovarian cancer cases, c.5123C > A in bilateral breast cancer and c.9117G > A in bilateral breast cancer and ovarian cancer. With respect to clinical–pathological characteristic, BRCA1/BRCA2 mutation carriers showed earlier onset age of breast tumour and higher risk of developing contra lateral breast cancer than non-informative cases. Moreover, association between either molecular subtype triple negative breast cancer or ovarian cancer and BRCA1 carriers was obtained.
Similar content being viewed by others
References
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781
Sanchez MJ, Payer T, De AR, Larranaga N, Capocaccia R, Martinez C (2010) Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol 21(Suppl 3):iii30–iii36
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792
Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130
Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665–676
Diez O, Gutierrez-Enriquez S, Balmana J (2010) Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Fam Cancer 9:187–191
John EM, Miron A, Gong G et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298:2869–2876
Kean-Cowdin R, Spencer FH, Xia LY et al (2005) BRCA1 variants in a family study of African–American and Latina women. Hum Genet 116:497–506
Plon SE, Eccles DM, Easton D et al (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282–1291
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502
Vaughn CP, Lyon E, Samowitz WS (2008) Confirmation of single exon deletions in MLH1 and MSH2 using quantitative polymerase chain reaction. J Mol Diagn. doi:10.2353/jmoldx.2008.080021
den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7–12
Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ (2013) BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist 18:518–524
Thomassen M, Blanco A, Montagna M et al (2012) Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat 132:1009–1023
Houdayer C, Caux-Moncoutier V, Krieger S et al (2012) Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 33:1228–1238
Zhang MQ (1998) Statistical features of human exons and their flanking regions. Hum Mol Genet 7:919–932
Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput. Biol 11:377–394
Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in Genie. J Comput. Biol 4:311–323
Vreeswijk MP, Kraan JN, van der Klift HM et al (2009) Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat 30:107–114
Gabaldó Barrios X, Sarabia Meseguer M, Alonso Romero JL et al (2014) Novel BRCA1 deleterious mutation (c.1918C > T) in familial breast and ovarian cancer syndrome who share a common ancestry. Fam Cancer 13:431–435
Takahashi H, Behbakht K, McGovern PE et al (1995) Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55:2998–3002
Musolino A, Bella MS, Bortesi B et al (2007) BRCA mutations, molecular markers and clinical variables in early-onset breast cancer: a population based study. Breast 16:280–292
Gutiérrez-Enríquez S, de la Hoya M, Martinez-Bouzas C et al (2007) Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer. Breast Cancer Res Treat 103:103–107
Diez O, Osorio A, Duran M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312
Lubinski J, Phelan CM, Ghadirian P et al (2004) Cancer variation associated with the possition of the mutation in the BRCA2 gene. Fam Cancer 3:1–10
Biswas K, Das R, EgginGton JM, Qiao H et al (2012) Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. Hum Mol Genet 21:3993–4006
de Juan Jiménez I, García Casado Z, Palanca Suela S et al (2013) Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Fam Cancer 4:767–777
ENIGMA consortium (2015) BRCA1/2 Gene variant classification criteria. Publishing ENIGMA consortium. https://enigmaconsortium.org/library/general-documents. Accessed 26 Mar 2015
Eggington JM, Bowles KR, Moyes K, Manley S, Esterling L, Sizemore S et al (2014) A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 86:229–237
Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtiginan S, Goldgar DE, Couch FJ (2012) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33(1):8–21
Diez O, Cornet M, Gutiérrez-Enríquez S et al (2007) Estudio de los genes BRCA1 y BRCA2 en 200 familias con cáncer de mama hereditario. Quím Clín 26(4):202–206
Sagi M, Eilat A, Ben AL et al (2011) Two BRCA1/2 founder mutations in Jews of Sephardic origin. Fam Cancer 10:50–63
Miramar MD, Calvo MT, Rodríguez A et al (2008) Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutation and a large genomic deletion in BRCA1. Breast Cancer Res Treat 11:353–358
Infante M, Duran M, Esteban-Cardenosa E et al (2006) High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-Leon (central Spain). J Hum Genet 54:611–617
Sanz DJ, Acedo A, Infante M et al (2010) A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 16:1957–1967
Esteban CE, Bolufer GP, Palanca SS et al (2008) Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain. Breast Cancer Res Treat 112:69–73
Salazar R, Cruz-Hernandez JJ, Sanchez-Valdivieso E et al (2006) BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain. Cancer Lett 233:172–177
Janavicius R (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1:397–412
Llort G, Munoz CY, Tuser MP et al (2002) Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat 19:307
Breast Cancer Information Core (BIC) publishing in BIC web. http://research.nhgri.nih.gov/bic/. Accessed 2013
Dutil J, Colon-Colon JL, Matta JL, Sutphen R, Echenique M (2012) Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet 205:242–248
Weitzel JN, Clague J, Martir-Negron A et al (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31:210–216
Ruiz de Garibay G, Gutierrez-Enriquez S, Garre P et al (2012) Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin. Breast Cancer Res Treat 133:273–283
Michels KB, Solomon CG, Hu FB et al (2003) Type 2 diabetes and subsequent incidence of breast cancer in the urses Health Study. Diabetes Care 26:1752–1758
Del Giudice ME, Fantus IG, Ezzat S et al (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111–120
Rogozinska-Szcepka J, Utracka-Hutka B, Grzybowska E, Maka B, Nowicka E, Smok-Ragankiewicz A, Zientek H, Steffen J, Wojciechowska-Lacka A (2004) BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Ann Oncol 15(9):1373–1376
Nicoletto MO, Donach M, de Nicolo A et al (2001) BRCA1 and BRCA2 mutations as prognostic factors in clinical practice and genetic counseling. Cancer Treat Rev 27:295–304
Mavaddat N, Barrowdale D, Andrulis IL et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21:134–147
Petrucelli N, Daly MB, Feldman GL (1998) BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. Publishing GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1247. Accessed 26 Sept 2013
Llort G, Chirivella I, Morales R et al (2015) SEOM clinical guidelines in Hereditary Breast and ovarian cancer. Clin Transl Oncol 17:956–961
Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB, O' Malley FP, Andrulis IL (2009) Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumor. Breast Cancer Res Treat 117:183–191
Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, Salisbury EL, Bilous AM, Byth K, Mann GJ (2010) Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families. Genes Chromosomes Cancer 49:1082–1094
Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascon A, Urioste M, Cazorla A, Díez O, Lerma E, Esteller M, Palacios J, Benítez J (2007) Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pahol 20:1298–1306
Simpson PT, Reis-Filho JS, Lambros MB, Jones C et al (2008) Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 215:231–244
Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ et al (2000) The pathology of familial breast cancer: histological features of cancer in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6:782–789
Petrucelli N, Daly MB, Feldman GL (1998) FACMG BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer September 4, 1998. Accessed September 26, 2013. GeneReviews® [Internet]
Oza A, Cibula D, Oaknin A, Poole C et al (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet Oncology 16(1):87–97
Acknowledgements
We would like to express our gratitude to the laboratory technicians Ángeles Moreno Locubiche, Patricia Pascual Gilabert and Teresa Manzano Baiazitova and the nurse Pilar Moya Martínez. We would also like to thank all residents who have contributed to this report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gabaldó Barrios, X., Sarabia Meseguer, .D., Marín Vera, M. et al. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical–pathological features in BRCA carriers and non-carriers. Familial Cancer 16, 477–489 (2017). https://doi.org/10.1007/s10689-017-9985-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-017-9985-x